Structural differences of amyloid-β fibrils revealed by antibodies from phage display

BMC Biotechnology

Volumn 15, Issue 1, 2015, Pages

  Droste, Patrick ^a,b   Frenzel, André ^a,c   Steinwand, Miriam ^a,d   Pelat, Thibaut ^e,f   Thullier, Philippe ^e   Hust, Michael ^a   Lashuel, Hilal ^g   Dübel, Stefan ^a  

^a TECHNICAL UNIVERSITY OF BRAUNSCHWEIG   (Germany)

^b CELERION   (United States)

^c YUMAB GmbH   (Germany)

^d Delenex Therapeutics AG   (Switzerland)

^e INSTITUT DE RECHERCHE BIOMÉDICALE DES ARMÉES   (France)

^f BIOTEM Parc d'Activités Bièvre Dauphine   (France)

^g EPFL   (Switzerland)

Author keywords

Abeta; Alzheimer's disease; A ; Beta amyloid; Immune library; Phage display; scFv

Indexed keywords

AGGREGATES; BINS; CONFORMATIONS; DIAGNOSIS; EPITOPES; GLYCOPROTEINS; LIBRARIES; NEURODEGENERATIVE DISEASES; OLIGOMERS; PEPTIDES; PROTEINS; SIZE EXCLUSION CHROMATOGRAPHY;

ABETA; ALZHEIMER'S DISEASE; BETA AMYLOIDS; PHAGE DISPLAY; SCFV;

ANTIBODIES;

ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; HUNTINGTIN; PAD172 F12 ANTIBODY; PAD213 A5 ANTIBODY; PAD233 E5 ANTIBODY; PAD236 H2 ANTIBODY; PAD97 D6 ANTIBODY; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; TAU PROTEIN; UNCLASSIFIED DRUG; AMYLOID; ANTIBODY; EPITOPE; PEPTIDE FRAGMENT;

ALPHA HELIX; ALZHEIMER DISEASE; AMINO TERMINAL SEQUENCE; AMYLOIDOSIS; ANIMAL EXPERIMENT; ANTIBODY AFFINITY; ANTIBODY PRODUCTION; ANTIBODY SPECIFICITY; ANTIGEN BINDING; ANTIGEN SPECIFICITY; ARTICLE; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; CROSS REACTION; EPITOPE MAPPING; GEL PERMEATION CHROMATOGRAPHY; MACACA FASCICULARIS; MALE; MOLECULAR PATHOLOGY; NEUROFILAMENT; NEUROPATHOLOGY; NONHUMAN; PHAGE DISPLAY; PROTEIN AGGREGATION; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN STRUCTURE; SIGNAL NOISE RATIO; AMINO ACID SEQUENCE; CHEMISTRY; GENETICS; HUMAN; IMMUNOLOGY; METABOLISM; PATHOLOGY; PROTEIN SECONDARY STRUCTURE; PROTEINOSIS;

ANIMALIA; MACACA FASCICULARIS;

ALZHEIMER DISEASE; AMINO ACID SEQUENCE; AMYLOID; AMYLOID BETA-PEPTIDES; ANTIBODIES; EPITOPES; HUMANS; PEPTIDE FRAGMENTS; PROTEIN AGGREGATION, PATHOLOGICAL; PROTEIN CONFORMATION; PROTEIN STRUCTURE, SECONDARY;

EID: 84935850991     PISSN: None     EISSN: 14726750     Source Type: Journal    
DOI: 10.1186/s12896-015-0146-8     Document Type: Article

References (78)

1. Fitzpatrick AL, Kuller LH, Lopez OL, Kawas CH, Jagust W. Survival following dementia onset: Alzheimer's disease and vascular dementia. J Neurol Sci. 2005;229-230:43-9.
2. Goedert M, Wischik CM, Crowther RA, Walker JE, Klug A. Cloning and sequencing of the cDNA encoding a core protein of the paired helical filament of Alzheimer disease: identification as the microtubule-associated protein tau. Proc Natl Acad Sci U S A. 1988;85:4051-5.
3. Kosik KS, Joachim CL, Selkoe DJ. Microtubule-associated protein tau (tau) is a major antigenic component of paired helical filaments in Alzheimer disease. Proc Natl Acad Sci U S A. 1986;83:4044-8.
4. Glenner GG, Wong CW. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun. 1984;120:885-90.
5. Masters CL, Multhaup G, Simms G, Pottgiesser J, Martins RN, Beyreuther K. Neuronal origin of a cerebral amyloid: neurofibrillary tangles of Alzheimer's disease contain the same protein as the amyloid of plaque cores and blood vessels. EMBO J. 1985;4:2757-63.
6. Selkoe DJ, Abraham CR, Podlisny MB, Duffy LK. Isolation of low-molecular-weight proteins from amyloid plaque fibers in Alzheimer's disease. J Neurochem. 1986;46:1820-34.
7. Seubert P, Vigo-Pelfrey C, Esch F, Lee M, Dovey H, Davis D, et al. Isolation and quantification of soluble Alzheimer's beta-peptide from biological fluids. Nature. 1992;359:325-7.
8. Harper JD, Lansbury Jr PT. Models of amyloid seeding in Alzheimer's disease and scrapie: mechanistic truths and physiological consequences of the time-dependent solubility of amyloid proteins. Annu Rev Biochem. 1997;66:385-407.
9. Jarrett JT, Berger EP, Lansbury Jr PT. The carboxy terminus of the. beta. amyloid protein is critical for the seeding of amyloid formation: Implications for the pathogenesis of Alzheimer's disease. Biochemistry (Mosc). 1993;32:4693-7.
10. Garzon-Rodriguez W, Sepulveda-Becerra M, Milton S, Glabe CG. Soluble Amyloid Aβ-(1-40) exists as a stable dimer at low concentrations. J Biol Chem. 1997;272:21037-44.
11. Roher AE, Chaney MO, Kuo Y-M, Webster SD, Stine WB, Haverkamp LJ, et al. Morphology and toxicity of Aβ-(1-42) dimer derived from neuritic and vascular Amyloid deposits of Alzheimer's disease. J Biol Chem. 1996;271:20631-5.
12. Bitan G, Fradinger EA, Spring SM, Teplow DB. Neurotoxic protein oligomers-what you see is not always what you get. Amyloid Int J Exp Clin Investig Off J Int Soc Amyloidosis. 2005;12:88-95.
13. Cleary JP, Walsh DM, Hofmeister JJ, Shankar GM, Kuskowski MA, Selkoe DJ, et al. Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat Neurosci. 2005;8:79-84.
14. Dahlgren KN. Oligomeric and fibrillar species of Amyloid-beta peptides differentially affect neuronal viability. J Biol Chem. 2002;277:32046-53.
15. Lesné S, Koh MT, Kotilinek L, Kayed R, Glabe CG, Yang A, et al. A specific amyloid-β protein assembly in the brain impairs memory. Nature. 2006;440:352-7.
16. Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, et al. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature. 2002;416:535-9.
17. Walsh DM, Lomakin A, Benedek GB, Condron MM, Teplow DB. Amyloid β-protein fibrillogenesis detection of a protofibrillar intermediate. J Biol Chem. 1997;272:22364-72.
18. Jan A, Adolfsson O, Allaman I, Buccarello A-L, Magistretti PJ, Pfeifer A, et al. Aβ42 Neurotoxicity is mediated by ongoing nucleated polymerization process rather than by discrete A 42 species. J Biol Chem. 2010;286:8585-96.
19. Ahmed M, Davis J, Aucoin D, Sato T, Ahuja S, Aimoto S, et al. Structural conversion of neurotoxic amyloid-β(1-42) oligomers to fibrils. Nat Struct Mol Biol. 2010;17:561-7.
20. Benilova I, Karran E, De Strooper B. The toxic Aβ oligomer and Alzheimer's disease: an emperor in need of clothes. Nat Neurosci. 2012;15:349-57.
21. Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide. Nat Rev Mol Cell Biol. 2007;8:101-12.
22. Kayed R, Head E, Thompson JL, McIntire TM, Milton SC, Cotman CW, et al. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science. 2003;300:486-9.
23. Kim T, Vidal GS, Djurisic M, William CM, Birnbaum ME, Garcia KC, et al. Human LilrB2 Is a β-Amyloid Receptor and Its Murine Homolog PirB Regulates Synaptic Plasticity in an Alzheimer's Model. Science. 2013;341:1399-1404.
24. Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M, et al. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci U S A. 1998;95:6448-53.
25. Walsh DM, Klyubin I, Fadeeva JV, Rowan MJ, Selkoe DJ. Amyloid-beta oligomers: their production, toxicity and therapeutic inhibition. Biochem Soc Trans. 2002;30:552-7.
26. Nelson PT, Braak H, Markesbery WR. Neuropathology and cognitive impairment in Alzheimer disease: a complex but coherent relationship. J Neuropathol Exp Neurol. 2009;68:1-14.
27. Fox NC, Freeborough PA, Rossor MN. Visualisation and quantification of rates of atrophy in Alzheimer's disease. Lancet. 1996;348:94-7.
28. Johnson KA, Fox NC, Sperling RA, Klunk WE. Brain imaging in Alzheimer disease. Cold Spring Harb Perspect Med. 2012;2:a006213.
29. Marshall GA, Monserratt L, Harwood D, Mandelkern M, Cummings JL, Sultzer DL. Positron emission tomography metabolic correlates of apathy in Alzheimer disease. Arch Neurol. 2007;64:1015-20.
30. Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, et al. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol. 2009;65:403-13.
31. Buckholtz NS. Perspective: in search of biomarkers. Nature. 2011;475:S8.
32. Colledge NR, Walker BR, Ralston S, Davidson S. Davidson's principles and practice of medicine. Edinburgh; New York: Churchill Livingstone/Elsevier; 2010.
33. Doody RS. Therapeutic standards in Alzheimer disease. Alzheimer Dis Assoc Disord. 1999;13 Suppl 2:S20-6.
34. Ferris SH. Evaluation of memantine for the treatment of Alzheimer's disease. Expert Opin Pharmacother. 2003;4:2305-13.
35. Pelat T, Hust M, Hale M, Lefranc M-P, Dübel S, Thullier P. Isolation of a human-like antibody fragment (scFv) that neutralizes ricin biological activity. BMC Biotechnol. 2009;9:60.
36. Laffly E, Danjou L, Condemine F, Vidal D, Drouet E, Lefranc M-P, et al. Selection of a Macaque Fab with framework regions like those in humans, high affinity, and ability to neutralize the Protective Antigen (PA) of Bacillus anthracis by binding to the segment of PA between residues 686 and 694. Antimicrob Agents Chemother. 2005;49:3414-20.
37. Pelat T, Hust M, Laffly E, Condemine F, Bottex C, Vidal D, et al. High-affinity, human antibody-like antibody fragment (Single-Chain Variable Fragment) neutralizing the Lethal Factor (LF) of Bacillus anthracis by inhibiting protective Antigen-LF complex formation. Antimicrob Agents Chemother. 2007;51:2758-64.
38. Schütte M, Thullier P, Pelat T, Wezler X, Rosenstock P, Hinz D, et al. Identification of a putative Crf splice variant and generation of recombinant antibodies for the specific detection of Aspergillus fumigatus. PLoS One. 2009;4:e6625.
39. Rülker T, Voß L, Thullier P, O' Brien LM, Pelat T, Perkins SD, et al. Isolation and characterisation of a human-like antibody fragment (scFv) that inactivates VEEV in vitro and in vivo. PLoS One. 2012;7, e37242.
40. Hülseweh B, Rülker T, Pelat T, Langermann C, Frenzel A, Schirrmann T, et al. Human-like antibodies neutralizing Western equine encephalitis virus. mAbs. 2014;6:718-27.
41. Miethe S, Rasetti-Escargueil C, Liu Y, Chahboun S, Pelat T, Avril A, et al. Development of neutralizing scFv-Fc against botulinum neurotoxin A light chain from a macaque immune library. mAbs. 2014;6:446-59.
42. Avril A, Froude J, Mathieu J, Pelat T, Thullier P. Isolation of antibodies from Non-human primates for clinical use. Curr Drug Discov Technol. 2014;11:20-7.
43. Bradbury ARM, Sidhu S, Dübel S, McCafferty J. Beyond natural antibodies: the power of in vitro display technologies. Nat Biotechnol. 2011;29:245-54.
44. Hust M, Meyer T, Voedisch B, Rülker T, Thie H, El-Ghezal A, et al. A human scFv antibody generation pipeline for proteome research. J Biotechnol. 2011;152:159-70.
45. Jäger V, Büssow K, Wagner A, Weber S, Hust M, Frenzel A, et al. High level transient production of recombinant antibodies and antibody fusion proteins in HEK293 cells. BMC Biotechnol. 2013;13:52.
46. Lee M, Bard F, Johnson-Wood K, Lee C, Hu K, Griffith SG, et al. Aβ42 immunization in Alzheimer's disease generates Aβ N-terminal antibodies. Ann Neurol. 2005;58:430-5.
47. Lemere CA, Beierschmitt A, Iglesias M, Spooner ET, Bloom JK, Leverone JF, et al. Alzheimer's disease Aβ vaccine reduces central nervous system Aβ levels in a non-human primate, the Caribbean Vervet. Am J Pathol. 2004;165:283-97.
48. Vasilevko V, Pop V, Kim HJ, Saing T, Glabe CC, Milton S, et al. Linear and conformation specific antibodies in aged beagles after prolonged vaccination with aggregated Abeta. Neurobiol Dis. 2010;39:301-10.
49. Bard F, Barbour R, Cannon C, Carretto R, Fox M, Games D, et al. Epitope and isotype specificities of antibodies to beta -amyloid peptide for protection against Alzheimer's disease-like neuropathology. Proc Natl Acad Sci U S A. 2003;100:2023-8.
50. Miller DL, Currie JR, Mehta PD, Potempska A, Hwang Y-W, Wegiel J. Humoral immune response to fibrillar beta-amyloid peptide. Biochemistry (Mosc). 2003;42:11682-92.
51. Bacskai BJ, Kajdasz ST, McLellan ME, Games D, Seubert P, Schenk D, et al. Non-Fc-mediated mechanisms are involved in clearance of amyloid-beta in vivo by immunotherapy. J Neurosci Off J Soc Neurosci. 2002;22:7873-8.
52. Dornieden S, Müller-Schiffmann A, Sticht H, Jiang N, Cinar Y, Wördehoff M, et al. Characterization of a single-chain variable fragment recognizing a linear epitope of Aβ: a biotechnical tool for studies on Alzheimer's disease? PLoS ONE. 2013;8:e59820.
53. Howlett DR, Perry AE, Godfrey F, Swatton JE, Jennings KH, Spitzfaden C, et al. Inhibition of fibril formation in beta-amyloid peptide by a novel series of benzofurans. Biochem J. 1999;340:283-9.
54. Ida N, Hartmann T, Pantel J, Schröder J, Zerfass R, Förstl H, et al. Analysis of heterogeneous A4 peptides in human cerebrospinal fluid and blood by a newly developed sensitive Western blot assay. J Biol Chem. 1996;271:22908-14.
55. Johnson-Wood K, Lee M, Motter R, Hu K, Gordon G, Barbour R, et al. Amyloid precursor protein processing and Aβ42 deposition in a transgenic mouse model of Alzheimer disease. Proc Natl Acad Sci U S A. 1997;94:1550-5.
56. Meinhardt J, Sachse C, Hortschansky P, Grigorieff N, Fändrich M. Abeta(1-40) fibril polymorphism implies diverse interaction patterns in amyloid fibrils. J Mol Biol. 2009;386(3):869-77.
57. Habicht G, Haupt C, Friedrich RP, Hortschansky P, Sachse C, Meinhardt J, et al. Directed selection of a conformational antibody domain that prevents mature amyloid fibril formation by stabilizing Aβ protofibrils. Proc Natl Acad Sci. 2007;104:19232-7.
58. Kayed R, Head E, Sarsoza F, Saing T, Cotman CW, Necula M, et al. Fibril specific, conformation dependent antibodies recognize a generic epitope common to amyloid fibrils and fibrillar oligomers that is absent in prefibrillar oligomers. Mol Neurodegener. 2007;2:18.
59. O'Nuallain B, Wetzel R. Conformational Abs recognizing a generic amyloid fibril epitope. Proc Natl Acad Sci. 2002;99:1485-90.
60. Frenkel D, Katz O, Solomon B. Immunization against Alzheimer's β-amyloid plaques via EFRH phage administration. Proc Natl Acad Sci U S A. 2000;97:11455-9.
61. Legleiter J, Czilli DL, Gitter B, DeMattos RB, Holtzman DM, Kowalewski T. Effect of different Anti-Aβ antibodies on Aβ Fibrillogenesis as assessed by atomic force microscopy. J Mol Biol. 2004;335:997-1006.
62. McLaurin J, Cecal R, Kierstead ME, Tian X, Phinney AL, Manea M, et al. Therapeutically effective antibodies against amyloid-beta peptide target amyloid-beta residues 4-10 and inhibit cytotoxicity and fibrillogenesis. Nat Med. 2002;8:1263-9.
63. Robert R, Dolezal O, Waddington L, Hattarki MK, Cappai R, Masters CL, et al. Engineered antibody intervention strategies for Alzheimer's disease and related dementias by targeting amyloid and toxic oligomers. Protein Eng Des Sel. 2009;22:199-208.
64. Solomon B, Koppel R, Hanan E, Katzav T. Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer beta-amyloid peptide. Proc Natl Acad Sci U S A. 1996;93:452-5.
65. Hilbich C, Kisters-Woike B, Reed J, Masters CL, Beyreuther K. Substitutions of hydrophobic amino acids reduce the amyloidogenicity of Alzheimer's disease beta A4 peptides. J Mol Biol. 1992;228:460-73.
66. Moreth J, Mavoungou C, Schindowski K. Passive anti-amyloid immunotherapy in Alzheimer's disease: What are the most promising targets? Immun Ageing A. 2013;10:18.
67. Prins ND, Scheltens P. Treating Alzheimer's disease with monoclonal antibodies: current status and outlook for the future. Alzheimers Res Ther. 2013;5:56.
68. Sato T, Kienlen-Campard P, Ahmed M, Liu W, Li H, Elliott JI, et al. Inhibitors of amyloid toxicity based on beta-sheet packing of Abeta40 and Abeta42. Biochemistry (Mosc). 2006;45:5503-16.
69. Jan A, Gokce O, Luthi-Carter R, Lashuel HA. The ratio of monomeric to aggregated forms of Aβ40 and Aβ42 is an important determinant of Amyloid-β aggregation, fibrillogenesis, and toxicity. J Biol Chem. 2008;283:28176-89.
70. "USDA Animal Welfare Act (AWA). 7 U.S.C. 2131 et seq., as amended and Health Research Extension Act of 1985 ('"Animals in Research"'). 1985."
71. National Research Council (US) Committee for the Update of the Guide for the Care and Use of Laboratory Animals. Guide for the Care and Use of Laboratory Animals. 8th ed. Washington (DC): National Academies Press (US); 2011.
72. Pelat T, Hust M, Thullier P. Obtention and engineering of non-human primate (NHP) antibodies for therapeutics. Mini Rev Med Chem. 2009;9:1633-8.
73. Frenzel A, Kügler J, Wilke S, Schirrmann T, Hust M. Construction of human antibody gene libraries and selection of antibodies by phage display. Methods Mol. Biol. Clifton NJ. 2014;1060:215-43.
74. Fuchs M, Kampfer S, Helmsing S, Spallek R, Oehlmann W, Prilop W, et al. Novel human recombinant antibodies against Mycobacterium tuberculosis antigen 85B. BMC Biotechnol. 2014;14:68.
75. Durocher Y, Perret S, Kamen A. High-level and high-throughput recombinant protein production by transient transfection of suspension-growing human 293-EBNA1 cells. Nucleic Acids Res. 2002;30:E9.
76. Frank R. Spot-synthesis: an easy technique for the positionally addressable, parallel chemical synthesis on a membrane support. Tetrahedron. 1992;48:9217-32.
77. Frank R. The SPOT-synthesis technique: synthetic peptide arrays on membrane supports-principles and applications. J Immunol Methods. 2002;267:13-26.
78. Tomaselli S, Esposito V, Vangone P, van Nuland NAJ, Bonvin AMJJ, Guerrini R, et al. The alpha-to-beta conformational transition of Alzheimer's Abeta-(1-42) peptide in aqueous media is reversible: a step by step conformational analysis suggests the location of beta conformation seeding. Chembiochem Eur J Chem Biol. 2006;7:257-67.